Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus TRINALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus TRINALIN.
DIPHENHYDRAMINE HYDROCHLORIDE vs TRINALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
TRINALIN is a combination of azatadine, a first-generation antihistamine that antagonizes histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
One tablet (azatadine 1 mg/pseudoephedrine 120 mg) orally every 12 hours. Not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
Terminal elimination half-life approximately 20-30 hours; clinical context: allows twice-daily dosing for sustained decongestant effect
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30%
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant